On the morning of July 30, the groundbreaking ceremony of Longyao Bio's "CAR-T and Cell Comprehensive Technology Industrialization Project" was held in Nanjing Jiangbei New Area Biomedical Valley.
Ribbon-cutting Ceremony of Longyao Biotechnology
Nanjing Jiangbei New Area is the only Chinese state-level new area in Jiangsu Province. As a key introduction project of Jiangbei New Area Biomedical Valley, this project will become an important transformation base for domestic biological cell scientific research achievements in the future. The commercialization and market application of cell technology will be a huge boon for cancer patients in the future. Jiangbei New Area has given great support to the project. Before the project commencement ceremony, Nanjing Biomedical Valley Development Center and Nanjing Longyao Biotechnology Co., Ltd. jointly signed a 30 million yuan construction fund support agreement.
Participants and leaders of various bureaus and committees in the park
Chen Chanmei, deputy director of the Nanjing Jiangbei New Area Management Committee, delivered a speech on the start of the project. Liu Xiaolin, chairman of the board of directors of China Biotechnology Services Holding Corporation, Ye Shengqin, chairman of Longyao Biotechnology, Professor Feng Zhenqing, director of the National Health Commission's Key Laboratory of Antibody Technology, and various bureau committees in Jiangbei New Area Representatives attended the event. Before the commencement ceremony, Mr. Liu Xiaolin, chairman of the board of directors of China Biotechnology Services Holding Company, introduced the company's situation, and Ye Shengqin, chairman of Longyao Biotechnology, gave a comprehensive introduction to the project. The Technology Industrialization Project" was officially launched.
Chen Chanmei, Deputy Director of Nanjing Jiangbei New Area Management Committee, delivered a speech
Liu Xiaolin, Chairman of the Board of Directors of China Biotechnology Services Holding Corporation, introduced the project
Ye Shengqin, Chairman of Longyao Biology, introduced the project
"CAR-T and Cell Comprehensive Technology Industrialization Project" is wholly-owned by Shanghai Longyao Biotechnology Co., Ltd.
The subsidiary Nanjing Longyao Biological Company invested and constructed it. On July 22, China Biotechnology Services Holding Company signed a proposed acquisition agreement for 67% of Shanghai Longyao Biotechnology Co., Ltd. The combination of capital and cutting-edge technologies, resources and original technologies that represent future trends will create more The miracle of life and infinite value, and accelerate the process of market transformation of biological cell scientific research results.
As an early domestic research company involved in tumor immune cell therapy, immune cell storage, health management, etc., Shanghai Longyao Biotechnology Co., Ltd. has established a complete tumor immune cell therapy technology and product system, and created a quality standard for cell preparation. It has established extensive scientific research cooperation with Shanghai Jiaotong University, Zhengzhou University, Xuzhou Medical University, Texas Southwest University and the First Affiliated Hospital of Zhengzhou University, Shanghai Public Health Clinical Center Affiliated to Fudan University, Affiliated Hospital of Xuzhou Medical University and other universities and clinical institutions.
The outstanding performance of CAR-T technology in the efficient fight against certain tumors has attracted much attention in the industry and is known as the "magic drug". In particular, the launch of two CAR-T products in the United States and the high price of treatment have accelerated the pace of the Chinese government's clinical application of CAR-T in the form of drugs. Shanghai Longyao has laid out the key technologies of CAR-T treatment in the early years, and has formed a strong team of scientists led by Professor Fu Yangxin (Professor Fu Yangxin is a candidate of the national "Thousand Talents Program", a famous tumor immunologist, Southwestern Medical Center of the University of Texas Chair Professor; Professor Yang Xuanming is a young talent of the national "Thousand Talents Program", a special researcher of the School of Life Science and Technology of Shanghai Jiaotong University, and a distinguished professor of Shanghai Oriental Scholars. Professor Gao Yanfeng is the winner of the Henan Province Outstanding Youth Fund and a professor of the School of Life Sciences of Zhengzhou University. ), in the whole pipeline R&D layout of CD19/20-CAR-T, general-purpose CAR-T, solid tumor CAR-T/TCR-T, and applied for a number of patents for key technologies, especially the self-developed new generation of CAR -T technology can effectively overcome the immunosuppressive microenvironment of solid tumors and metastatic tumors, and enhance the efficacy of CAR-T in the treatment of solid tumors. Shanghai Longyao Biology is improving various procedures and actively promoting the application and registration of products in accordance with the requirements of the specification.